7043-10-9

Basic information

• Product Name: 4(1H)-Pyrimidinone, 2-cyclopropyl-6-methyl- (9CI)
• Synonyms: 4(1H)-Pyrimidinone, 2-cyclopropyl-6-methyl- (9CI)
• CAS NO: 7043-10-9
• Molecular Formula: C₈H₁₀N₂O
• Molecular Weight: 150.1778
• Product Categories: PYRIMIDINE
• Mol File: 7043-10-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 191-193 °C
• Boiling Point: 253.5±23.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 9.80±0.50(Predicted)
• CAS DataBase Reference: 4(1H)-Pyrimidinone, 2-cyclopropyl-6-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 2-cyclopropyl-6-methyl- (9CI)(7043-10-9)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 2-cyclopropyl-6-methyl- (9CI)(7043-10-9)

Safety Data

• Hazardous Substances Data: 7043-10-9(Hazardous Substances Data)

Upstream product

• 54070-74-5 cyclopropanecarboxamidine 
• 141-97-9 ethyl acetoacetate 
• 477904-80-6 cyclopropanecarboximidamidine hydrochloride 
• 57297-29-7 cyclopropylcarboxamidine hydrochloride 
• 105-45-3 acetoacetic acid methyl ester 

Relevant articles and documents

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.